JBIO: Aerovate Growth-Adjusted Market Cap to Net Income

Brandmark of Aerovate Therapeutics Inc (JBIO)

Geopolitical strife and sanctions are severely hindering the development of immune drugs and international trials. Aerovate Therapeutics Inc (JBIO) stock dynamics are independent of the economy but sensitive to borrowing costs. The failure of phase 2b/3 trials crashed the valuation, forcing the business into an emergency restructuring. The P/E growth potential ratio reflects the immediate market reaction, with the metric currently standing at 0.00.

JBIO Aerovate Therapeutics, Inc.: Price/Earnings to Growth Ratio in the range 04/30/2025 - 11/18/2026

Metric breakdowns and analytics for Aerovate (JBIO)

General company analysis:JBIO - Aerovate
Signature product of Aerovate Therapeutics, Inc.

For Aerovate Therapeutics Inc (JBIO), this indicator for identifying undervalued growth companies serves as a tool to evaluate the effectiveness of management's new strategy following restructuring. The PEG ratio compares the current P/E multiple with earnings growth rates to determine whether the market price is fair relative to business dynamics; a value below one signals that the asset is undervalued, which is critical when searching for new growth drivers.

Competing companies

ARGX (Argenx) - Growth-Adjusted Payback Ratio|PEG Multiple BNTX (biontech.de)|Growth-Adjusted Market Cap to Net Income Abivax S.A. (ABVX)|ADMA - Price/Earnings to Growth Ratio|Protagonist Therapeutics, Inc. (PTGX) - Price/Earnings to Growth Multiple|Immunovant Therapeutics (IMVT) - Price/Earnings to Growth Ratio|Price/Earnings to Growth Multiple Kiniksa Pharmaceuticals|Price/Earnings to Growth Multiple GRFS|PEG Multiple adaptivebiotech.com|Price/Earnings to Growth Ratio Celldex (CLDX)|Aurinia Pharmaceuticals Inc. - Growth-Adjusted P/E Ratio|PEG Multiple BCRX (biocryst.com)|Vera Therapeutics, Inc. (VERA) - Price to Earnings Adjusted for Growth Rate|Dianthus Therapeutics, Inc. - PEG Multiple|Market Cap to Earnings and Growth Ratio PHVS|ABCL: PEG Multiple|Price to Earnings Adjusted for Growth Rate Tourmaline Corp (TRML)|PGEN (precigen.com) - PEG Multiple|PEG Multiple Pharming Corp|Price/Earnings to Growth Multiple NKTR (Nektar)|UPB (Upstream Bio Inc) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Zenas Bio ZBIO|IMNM: Growth-Adjusted P/E Ratio|GOSS - Price/Earnings to Growth Ratio|Growth-Adjusted Market Cap to Net Income KalVista Pharmaceuticals KALV|Septerna (SEPN) - Price/Earnings to Growth Ratio|pieris.com - Growth-Adjusted Payback Ratio|SVRA (Savara Inc) - PEG Multiple|RIGL: Growth-Adjusted Payback Ratio|PEG Multiple ANAB|ATXS (Astria Pharma) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio enGene Holdings Inc. ENGN|PEG Multiple RAPT Therapeutics Inc. RAPT|Aclaris Therapeutics, Inc - PEG Multiple|Price to Earnings Adjusted for Growth Rate Kyverna Therapeutics Inc.|TLSA: PEG Multiple|CABA - Growth-Adjusted Market Cap to Net Income|VTYX (ventyxbio.com) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Theratechnologies Inc. THTX|Price/Earnings to Growth Multiple AVTX (avalotx.com)|Price/Earnings to Growth Multiple Eledon Pharmaceuticals, Inc. ELDN|Price/Earnings to Growth Ratio Agenus, Inc AGEN|Climb Bio Inc - Price/Earnings to Growth Ratio|Zura Bio Limited - PEG Multiple|Growth-Adjusted Market Cap to Net Income aTyr Pharma, Inc. ATYR|ADAG: PEG Multiple|Market Cap to Earnings and Growth Ratio IMA (ImageneBio)|Price/Earnings to Growth Multiple STTK|EQ: Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Connect Pharma (CNTB)|PEG Multiple Immunic Therapeutics (IMUX)|PEG Multiple ATRA (Atara Biotherapeutics)|Growth-Adjusted Payback Ratio IFRX|XFOR (X4 Pharma) - Price to Earnings Adjusted for Growth Rate|Growth-Adjusted Payback Ratio ACET (adicetbio.com)|CELU: PEG Multiple|inmunebio.com (INMB) - PEG Multiple|BRNS (Barinthus Biotherapeutics PLC) - PEG Multiple|KZR: Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio SAB Biotherapeutics, Inc. (SABS)|AKTX (Akari Therapeutics plc) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Enlivex Therapeutics Ltd ENLV|QTTB - Price/Earnings to Growth Multiple|geovax.com - PEG Multiple|Growth-Adjusted Payback Ratio EDSA (Edesa Biotech Inc)|IBIO: PEG Multiple|Carisma Tx (CARM) - PEG Multiple|XTLB (XTL Biopharmaceuticals) - PEG Multiple|BOLT: Growth-Adjusted Payback Ratio|Price/Earnings to Growth Multiple HCWB (HCW Biologics, Inc.)|PEG Multiple Aptevo (APVO)|PEG Multiple AIM (aimimmuno.com)|PEG Multiple Aditxt Corp ADTX|GRI: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio XRTX (xortx.com)|Vyome Holdings Inc. (HIND) - Price/Earnings to Growth Ratio|Revelation Bio (REVB) - PEG Multiple|INDP (Indaptus Corp) - PEG Multiple|SCNI: Growth-Adjusted Payback Ratio|PEG Multiple CALI|Price/Earnings to Growth Multiple Affimed N.V. AFMD|Price/Earnings to Growth Ratio Allakos ALLK|HOOK: Growth-Adjusted P/E Ratio|IGMS - Price/Earnings to Growth Ratio|Growth-Adjusted Market Cap to Net Income iTeos Therapeutics ITOS|Ocean Biomedical (OCEA) - Price/Earnings to Growth Ratio|tcbiopharm.com (TCBP) - PEG Multiple|THRD (Third Harmonic Bio Inc.) - PEG Multiple